BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a hold rating to a buy rating in a report issued on Thursday morning.

Several other brokerages have also recently commented on MNKD. Leerink Swann assumed coverage on MannKind in a report on Monday, March 4th. They set an outperform rating and a $3.00 target price on the stock. Svb Leerink assumed coverage on MannKind in a report on Monday, March 4th. They set an outperform rating and a $3.00 target price on the stock. Finally, ValuEngine upgraded MannKind from a sell rating to a hold rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $3.06.

Shares of MNKD stock opened at $2.20 on Thursday. The firm has a market cap of $419.65 million, a PE ratio of -3.73 and a beta of 2.68. MannKind has a 52 week low of $0.94 and a 52 week high of $3.04.

MannKind (NASDAQ:MNKD) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.28). During the same period in the prior year, the company posted ($0.28) earnings per share. On average, research analysts expect that MannKind will post -0.32 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of MannKind by 9.0% during the fourth quarter. Bank of New York Mellon Corp now owns 433,294 shares of the biopharmaceutical company’s stock worth $459,000 after purchasing an additional 35,721 shares during the last quarter. Dupont Capital Management Corp grew its holdings in shares of MannKind by 11.9% during the fourth quarter. Dupont Capital Management Corp now owns 339,203 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 36,203 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in shares of MannKind by 196.1% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 55,407 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 36,694 shares during the period. CAPROCK Group Inc. acquired a new position in shares of MannKind during the fourth quarter valued at $42,000. Finally, Virtu Financial LLC acquired a new position in shares of MannKind during the fourth quarter valued at $50,000. Institutional investors own 33.37% of the company’s stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Further Reading: What is Call Option Volume?

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.